West Pharmaceutical Services, Inc. WST
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.55% | 12.38% | 11.23% | 6.25% | 4.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.55% | 12.38% | 11.23% | 6.25% | 4.92% |
| Cost of Revenue | 9.03% | 9.75% | 8.28% | 3.98% | 3.78% |
| Gross Profit | 18.93% | 17.21% | 16.83% | 10.57% | 7.05% |
| SG&A Expenses | 17.05% | 21.31% | 20.25% | 16.36% | 6.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -311.11% | -100.00% | -233.33% | 44.44% | -52.63% |
| Total Operating Expenses | 10.06% | 11.34% | 9.94% | 5.91% | 4.15% |
| Operating Income | 21.86% | 16.28% | 16.19% | 7.60% | 7.88% |
| Income Before Tax | 30.85% | 16.02% | 17.60% | 2.52% | 1.98% |
| Income Tax Expenses | 34.45% | 16.76% | 23.44% | 13.12% | 18.92% |
| Earnings from Continuing Operations | 29.94% | 15.83% | 16.16% | 0.20% | -1.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.94% | 15.83% | 16.16% | 0.20% | -1.58% |
| EBIT | 21.86% | 16.28% | 16.19% | 7.60% | 7.88% |
| EBITDA | 19.75% | 15.35% | 14.99% | 8.16% | 8.24% |
| EPS Basic | 32.05% | 17.07% | 17.11% | 1.17% | -0.26% |
| Normalized Basic EPS | 22.97% | 17.06% | 17.19% | 8.65% | 9.17% |
| EPS Diluted | 31.94% | 16.86% | 17.37% | 1.45% | 0.32% |
| Normalized Diluted EPS | 23.00% | 17.18% | 17.54% | 9.05% | 9.60% |
| Average Basic Shares Outstanding | -1.42% | -1.00% | -0.79% | -0.96% | -1.30% |
| Average Diluted Shares Outstanding | -1.44% | -1.10% | -1.09% | -1.32% | -1.69% |
| Dividend Per Share | 4.76% | 4.82% | 4.88% | 4.94% | 5.00% |
| Payout Ratio | -0.20% | -0.10% | -0.11% | 0.03% | 0.05% |